DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma. The trial will enroll ...

Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...

eye surgery Study shows reductions in intraocular pressures and antiglaucoma medication use. Intravitreal bevacizumab administration improves outcomes, and may reduce both intraocular pressure (IOP) ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Anterior chamber paracentesis may be an effective option to reduce IOP spikes after intravitreal ...